Industry Roundup
This article was originally published in The Tan Sheet
Executive Summary
PowerBar plant closing; Medifast, investor agree on board changes; BioPharmX announces IPO; Mérieux expands southeast U.S. testing; more news in brief.
You may also be interested in...
Omega-3 Petition Seeks Unqualified Blood Pressure, CHD Claims
The trade group Global Organization for EPA and DHA Omega-3 petitions FDA for an unqualified health claim related to reduced blood pressure as a surrogate marker for coronary heart disease risk.
In Brief
FDA finalizes OTC dosing guidance
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.